Highlights on nivolumab plus ipilimumab vs EXTREME in 1st-line high-risk squamous cell carcinoma of the head and neck: The CheckMate 651 study
ESMO 2021: CheckMate 651 study
Share.
About Author
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
